TU
OREX

TDAM USA’s Orexigen Therapeutics, Inc. OREX Stock Holding History

TDAM USA’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,590
Closed -$125K – 448
2015
Q1 		$125K Buy
1,590
+102
+7% +$6.33K 0.01% 393
2014
Q4 		$90K Buy
1,488
+250
+20% +$12.6K ﹤0.01% 314
2014
Q3 		$53K Buy
1,238
+200
+19% +$10.7K ﹤0.01% 315
2014
Q2 		$64K Sell
1,038
-1
-0.1% -$58 ﹤0.01% 321
2014
Q1 		$68K Hold
1,039
– – ﹤0.01% 319
2013
Q4 		$58K Sell
1,039
-51
-5% -$2.87K ﹤0.01% 307
2013
Q3 		$67K Buy
+1,090
New +$73.8K ﹤0.01% 297

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TDAM USA's OREX Position: Q2 2015 in Review

TDAM USA sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 1,590 shares — an estimated $125K sold.

TDAM USA first reported a position in OREX in Q3 2013 and held it in 7 quarters. The position peaked at $125K in Q1 2015. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • TDAM USA reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • TDAM USA sold 1,590 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $125K.
  • TDAM USA first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and held it in 7 quarters.
  • TDAM USA's Orexigen Therapeutics, Inc. position peaked at $125K in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on TDAM USA's 13F filing for Q2 2015, filed 11 Aug 2015.